Tryton Stent Implanted in First Cases in Portugal and Austria

DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to
definitively treat bifurcation lesions, today announced that the Tryton®
stent has been implanted for the first time in Portugal and Austria.

Francisco Pereira Machado, M.D., of Hospital da Luz in Lisbon performed
the first implant in Portugal.

“The Tryton Side Branch Stent is a simple approach to secure and dilate
the side branch with optimal scaffolding of its ostium. Its use makes
the placement and deployment of the main vessel stent easy,” said Dr.
Machado. “When there is involvement of both the main vessel and the side
branch, and when, for any reason, you choose to go for two stents, think
of dedicated stents. Keep it simple.”

Olev Luha, M.D., Ph.D., from the LKH University Hospital in Graz was the
first to use the Tryton Side Branch Stent in Austria and has implanted
four Tryton stents during four different procedures.

“I am pleased to have had the opportunity to start using the Tryton Side
Branch Stent. The Tryton is easy to use and allows for a predictable
treatment of bifurcation lesions, which are some of the most complex
lesions that we get to treat. Going forward, I will use the Tryton Side
Branch Stent in my daily practice,” said Dr. Luha.

“The rapid adoption of the Tryton Side Branch Stent is extremely
gratifying. The system has now been implanted in more than 750 European
patients,” said J. Greg Davis, president and CEO of Tryton Medical. “We
are very pleased that the Tryton® stent is now available in Portugal and
Austria, giving physicians in those countries a dedicated strategy for
these difficult-to-treat areas of disease, which are a frequent
occurrence – approximately one in every four cases.”

About the Tryton Side Branch Stent System

The Tryton Side Branch Stent System is designed to offer a dedicated
strategy for treating atherosclerotic lesions in the side branch at the
site of a bifurcation. These areas of the vascular system are a common
location for plaque and are particularly challenging to treat with
currently available stent systems. Approximately twenty-two percent of
patients treated for coronary artery disease have diseased bifurcated
lesions.

Tryton’s highly deliverable cobalt chromium stent is deployed in the
side branch artery using a standard single-wire balloon-expandable stent
delivery system. A conventional drug-eluting stent is then placed in the
main vessel.

The Tryton Side Branch Stent System demonstrated excellent six-month
clinical results in a first-in-man study of the system in 30 patients,
with no restenosis occurring in the side branch artery. The stent system
has received CE Mark approval in Europe and is not approved in the
United States.

About Tryton Medical, Inc.

Tryton Medical, Inc., located in Durham, N.C., is a leading developer of
novel stent systems for the treatment of bifurcation lesions. The
company`s Side Branch Stent System, approved for sale in Europe, is
designed to offer a dedicated strategy for treating these challenging
cases. The privately held company is backed by Spray Ventures, PTV
Sciences, and RiverVest Ventures. For more information please visit trytonmedical.com.